All in all, the findings lay the foundation for the development of drugs that boost S1P to treat or prevent coronary artery disease, the researchers concluded. More information: Onorina L. Manzo ...

Researchers investigated the potential association between plasma apolipoprotein M (APOM) levels and the risk of adverse ...

In its first phase 3 readout, oral S1P receptor modulator etrasimod met its objectives in patients with moderately-to-severely active ulcerative colitis, who had previously failed or were ...

Orally-active S1P agonist Zeposia (ozanimod) has been submitted to the FDA as a treatment for adults with moderately to severely active ulcerative colitis (UC), with a decision from the US ...

Viatris will be the exclusive owner of cenerimod rights in Japan and APAC (ex-China). Viatris gained exclusive rights to cenerimod in all other territories from Idorsia through a research and ...